Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Burlington Stores Inc (BURL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Burlington Stores Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Burlington Stores Inc trades at $312.75 (market cap $19.90B). The key difference: Burlington Stores Inc is far larger — about 4.4× ACADIA Pharmaceuticals Inc.'s market cap. Which is the better fit depends on your goals.
| ACAD | BURL | |
|---|---|---|
Market Cap | $4.49B | $19.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $347.82 |
52-Week Low | $20.06 | $242.43 |
Enterprise Value | $3.69B | $25.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Burlington Stores (BURL) trades at $312.36, showing modest daily decline of -0.26% but maintaining strong fundamental performance with consistent earnings beats. The stock exhibits bearish technical signals despite positive analyst sentiment, with 94% buy ratings and a $364.40 consensus price target. Recent Q1 2026 results exceeded expectations with $2.01 EPS versus $1.80 expected, marking the 14th consecutive quarter of double-digit earnings growth.
BURL presents a compelling growth story with expanding margins and store expansion plans, though technical indicators suggest near-term caution. The stock's premium valuation (P/E 32.14) reflects growth expectations, while competitive pressures and consumer spending sensitivity remain key risks. Upside potential exists toward analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →
